Halozyme Therapeutics Inc. (NASDAQ:HALO) rose 2% during trading on Monday . The company traded as high as $10.27 and last traded at $10.18, with a volume of 379,066 shares. The stock had previously closed at $9.98.

HALO has been the subject of a number of research reports. Jefferies Group restated a “sell” rating and issued a $6.75 price target on shares of Halozyme Therapeutics in a report on Tuesday, May 10th. Canaccord Genuity restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, May 10th. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, May 10th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $15.00 price target on shares of Halozyme Therapeutics in a report on Thursday, June 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. Halozyme Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $15.68.

The firm’s market cap is $1.32 billion. The firm’s 50-day moving average price is $9.59 and its 200-day moving average price is $9.39.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.06. During the same quarter in the previous year, the firm posted $0.02 earnings per share. The business earned $33.30 million during the quarter, compared to the consensus estimate of $29.94 million. The company’s revenue was down 23.3% compared to the same quarter last year. On average, equities research analysts anticipate that Halozyme Therapeutics Inc. will post ($0.91) EPS for the current fiscal year.

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.